Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Detection Raises $1.5M for Sepsis, GI Test Development

NEW YORK (GenomeWeb News) – Molecular diagnostic firm Molecular Detection today said that it has completed a $1.5 million financing round to advance its tests for detecting sepsis and gastrointestinal diseases.

The Detect-Ready sepsis panel is designed to detect a range of targets to pinpoint the underlying infection and enable faster treatment, while the Detect-Ready gastrointestinal panel is being developed to be the first molecular diagnostic test able to distinguish the source of an infection without the use of other tests, the company said.

The Detect-Ready technology is real-time PCR-based, and is compatible with a number of real-time PCR platforms from Roche, Abbott, Qiagen, and Cepheid.

Beta testing for both the sepsis and GI panels have started in selected healthcare facilities, the Wayne, Penn.-headquartered firm added.

"The superior performance of the unique differential diagnosis technology that is the foundation for all of our tests was recently reconfirmed in an independent study comparing MDI's Detect-Ready MRSA panel to a market leading competitor," Molecular Detection Chairman and CEO Todd Wallach said in a statement. "We believe that the Detect-Ready technology provides more accurate and useful information to healthcare providers in an economical, rapid and easy-to-use format, resulting in benefits for hospitals, payers, and patients alike."

The Detect-Ready MRSA panel is already available in parts of Europe and Australia.

All existing investors participated in the round, including MentorTech Ventures, Robin Hood Ventures, Elm Spring Holdings, and the Mid-Atlantic Angel Group.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.